Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry TORONTO , Oct. 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of internationally recognized leaders in stem cell biology, regenerative medicine, neuroscience and small molecule chemistry who will help guide the company's long-term scientific exploration of regeneration, aging and neurodegenerative biology. “Much of my scientific career has been devoted to understanding how cellular polarity governs stem cell function and tissue regeneration,” said Michael Rudnicki , OC, FRS, co-founder and chief discovery officer. “We are only beginning to appreciate how these fundamental biological processes may influence aging, neurodegeneration and other conditions beyond muscle disease. I am thrilled to welcome this remarkable group of scientists to our SAB and look forward to exploring new scientific questions that could deepen our understanding of regenerative biology.” The Board will advise on emerging discoveries in stem cell biology, molecular signaling and disease pathology, including how aging influences regenerative capacity and how mechanisms governing stem cell behavior may contribute to neurodegenerative disease. “We are honored to bring together this exceptional group of scientists to serve on Satellos’ Scientific Advisory Board ,” said Satellos Chief Scientific Officer Phil Lambert , Ph.D. “The SAB will help deepen our understanding of how cellular polarity influences tissue maintenance, regeneration and disease across multiple biological systems. Its collective expertise will broaden our scientific perspective as we explore aging and neuroscience and continue advancing our understanding of regenerative biology.” The members of the Satellos SAB are: Janet Rossant , CC, Ph.D., FRS, FRSC, Chief of Research Emeritus and Senior Scientist Emeritus, The Hospital for Sick Children (Satellos SAB Chair) Rima Al -awar, Ph.D., Vice Provost, Research Innovations and Commercialization, New York University Abu Dhabi Sebastian Jessberger , M.D., Professor of Neurosciences and Director, Brain Research Institute , University of Zurich Mary Mader , Ph.D., President, MM Molecular Pharma Consulting LLC Lee Rubin , Ph.D., Professor of Stem Cell and Regenerative Biology, Harvard University ; Co-director, Harvard Stem Cell Institute Marius Wernig , M.D., Ph.D., Professor of Pathology and Chemical and Systems Biology, Stanford University Full biographies of the Scientific Advisory Board members are available on the Company's website . ABOUT SATELLOS BIOSCIENCE INC. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment for Duchenne muscular dystrophy (DMD) in two Phase 2 clinical trials, BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD. The FDA also cleared an Investigational New Drug (IND) application for the clinical evaluation of forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com and connect with Satellos on X , LinkedIn , Facebook and Instagram . NOTICE ON FORWARD-LOOKING STATEMENTS This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the possibility of pursuing regulatory approval for forazapadin, including a potential accelerated approval pathway; anticipated benefits to patients from forazapadin; the enrollment in, advancement and timing of results of forazapadin through clinical trials, including the BASECAMP, TRAILHEAD and Phase 2 FSHD clinical trials, and the timing of release of related clinical trial data; the potential of Satellos’ approach in other degenerative muscle diseases and Satellos’ plans to pursue additional muscle diseases and injury conditions in future clinical development; Satellos' technologies and drug development plans; and Satellos’ expectation for broader use of International Nonproprietary Name in future scientific, regulatory and corporate communications. All statements that are, or informat